Association of immune globulin intravenous and thromboembolic adverse events

Am J Hematol. 2017 Apr;92(4):E44-E45. doi: 10.1002/ajh.24644. Epub 2017 Feb 13.

Authors

Mikhail V Ovanesov¹, Mikhail D Menis², Dorothy E Scott¹, Richard Forshee², Steven Anderson², Wilson Bryan¹, Basil Golding¹

Affiliations

¹ Office of Tissues and Advanced Therapies, CBER, US Food and Drug Administration, Silver Spring, Maryland.
² Office of Biostatistics and Epidemiology, CBER, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 28066925
DOI: 10.1002/ajh.24644

No abstract available

Publication types

Letter

MeSH terms

Female
Humans
Immunoglobulins, Intravenous / administration & dosage
Immunoglobulins, Intravenous / adverse effects*
Male
Thromboembolism / blood
Thromboembolism / chemically induced*

Substances

Immunoglobulins, Intravenous